Company Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in psychiatric and neurological disorders in the United States.
The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing lumateperone, which is in Phase 3 clinical trial for the treatment of major depressive disorder, as well as schizophrenia in pediatric patients, bipolar disorder, and irritability associated with autism spectrum disorder.
In addition, the company develops lenrispodun (ITI-214) in Phase 2 clinical trial for the treatment of Parkinson’s disease; ITI-1284-ODT-SL in Phase 2 trial for the treatment of generalized anxiety disorder, and psychosis and agitation in patients with Alzheimer’s disease; ITI-1020 in Phase 1 trial for cancer immunotherapy; and ITI-1549 in preclinical studies for mood and anxiety disorders.
It distributes its products through third-party wholesale drug distributors. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in Bedminster, New Jersey.
| Country | United States |
| Founded | 2002 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 860 |
| CEO | Sharon Mates |
Contact Details
Address: 135 Route 202/206, Suite 6 Bedminster, New Jersey 07921 United States | |
| Phone | 646 440 9333 |
| Website | intracellulartherapies.com |
Stock Details
| Ticker Symbol | ITCI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001567514 |
| CUSIP Number | 46116X101 |
| ISIN Number | US46116X1019 |
| Employer ID | 36-4742850 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sharon Mates Ph.D. | Co-Founder, Chairman and Chief Executive Officer |
| Michael I. Halstead J.D. | President |
| Dr. Robert E. Davis Ph.D. | Senior Vice President and Chief Scientific Officer |
| Juan Fernando Sanchez M.D. | Vice President of Corporate Communications and Investor Relations |
| Karen Patruno Sheehy Esq. | Senior Vice President and Chief Compliance Officer |
| John P. Condon | Senior Vice President, General Counsel and Secretary |
| Dr. Michael Olchaskey Pharm.D. | Senior Vice President and Head of Regulatory Affairs |
| John A. Bardi | Senior Vice President of Market Access, Policy and Government Affairs |
| Dr. Willie R. Earley M.D. | Senior Vice President and Head of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2025 | 8-K | Current Report |
| Mar 20, 2025 | 10-K/A | [Amend] Annual report |
| Mar 18, 2025 | 8-K | Current Report |
| Mar 18, 2025 | 144 | Filing |
| Mar 17, 2025 | 144 | Filing |
| Mar 7, 2025 | DFAN14A | Filing |
| Mar 3, 2025 | 8-K | Current Report |
| Feb 25, 2025 | DFAN14A | Filing |
| Feb 21, 2025 | 10-K | Annual Report |
| Feb 21, 2025 | 8-K | Current Report |